Trillium Therapeutics — Intralesional administration of the CD47 antagonist TTI-621 (SIRPαFc) induces responses in bothinjected and non-injected lesions in patients with relapsed/refractory mycosis fungoides and Sézary Syndrome: Interim results of a multicenter phase I trial
Home » Resources » Trillium Therapeutics — Intralesional administration of the CD47 antagonist TTI-621 (SIRPαFc) induces responses in bothinjected and non-injected lesions in patients with relapsed/refractory mycosis fungoides and Sézary Syndrome: Interim results of a multicenter phase I trial
Trillium Therapeutics — Intralesional administration of the CD47 antagonist TTI-621 (SIRPαFc) induces responses in bothinjected and non-injected lesions in patients with relapsed/refractory mycosis fungoides and Sézary Syndrome: Interim results of a multicenter phase I trial
Trillium Therapeutics — Intralesional administration of the CD47 antagonist TTI-621 (SIRPαFc) induces responses in bothinjected and non-injected lesions in patients with relapsed/refractory mycosis fungoides and Sézary Syndrome: Interim results of a multicenter phase I trial2021-03-242021-10-11/wp-content/uploads/2022/02/canopy-logo-2022-white.pngCanopy Biosciences/wp-content/uploads/2022/02/canopy-logo-2022-white.png200px200px
